Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Kidney diseases are a severe and growing problem worldwide, with a lack of effective treatments often leading to dialysis, transplantation and high costs to health care systems.
Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
March 28, 2023
Chinook Therapeutics to Present at the Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
March 23, 2023
Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023
March 7, 2023
Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
April 4, 2023 at 10:45 AM EDT
Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days
March 14, 2023 at 3:20 PM EDT
Oppenheimer 33rd Annual Healthcare Conference